It's not clear whether there's a true causal association.
We obviously have worked with the FDA and we're moving forward to make this information available to health care professionals and patients so that informed treatment decisions can be made.
We made the decision that settling was appropriate to avoid the expense and distraction of protracted litigation.
The decision to enter the settlement was made so that we could avoid the expense and the distraction that's often associated with potentially protracted litigation.
It raises awareness and encourages them to seek medical attention if they think they have a particular disease.